Physician profile
Mark Eric Hahn
NPI 1831272640
$464.70
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $127 · 2021: $52.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $108.29 | 2019 | |
| Foundation Medicine, INC. | $70.74 | 2020 | |
| Abbvie INC. | $69.46 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $46.64 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $32.56 | 2019 | |
| Emd Serono, INC. | $27.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.21 | 2019 | |
| Clovis Oncology, INC. | $24.79 | 2020 | |
| Janssen Biotech, INC. | $14.19 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.